GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Tong Ren Tang Chinese Medicine Co Ltd (HKSE:03613) » Definitions » Return-on-Tangible-Equity

Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) Return-on-Tangible-Equity : 14.95% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Beijing Tong Ren Tang Chinese Medicine Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Beijing Tong Ren Tang Chinese Medicine Co's annualized net income for the quarter that ended in Dec. 2023 was HK$549 Mil. Beijing Tong Ren Tang Chinese Medicine Co's average shareholder tangible equity for the quarter that ended in Dec. 2023 was HK$3,670 Mil. Therefore, Beijing Tong Ren Tang Chinese Medicine Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 14.95%.

The historical rank and industry rank for Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Equity or its related term are showing as below:

HKSE:03613' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 14.69   Med: 20.65   Max: 22.15
Current: 14.89

During the past 13 years, Beijing Tong Ren Tang Chinese Medicine Co's highest Return-on-Tangible-Equity was 22.15%. The lowest was 14.69%. And the median was 20.65%.

HKSE:03613's Return-on-Tangible-Equity is ranked better than
73.77% of 938 companies
in the Drug Manufacturers industry
Industry Median: 6.345 vs HKSE:03613: 14.89

Beijing Tong Ren Tang Chinese Medicine Co Return-on-Tangible-Equity Historical Data

The historical data trend for Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Tong Ren Tang Chinese Medicine Co Return-on-Tangible-Equity Chart

Beijing Tong Ren Tang Chinese Medicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.48 19.51 19.24 18.72 14.69

Beijing Tong Ren Tang Chinese Medicine Co Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.33 12.84 25.10 15.04 14.95

Competitive Comparison of Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Equity falls into.



Beijing Tong Ren Tang Chinese Medicine Co Return-on-Tangible-Equity Calculation

Beijing Tong Ren Tang Chinese Medicine Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=540.393/( (3544.78+3810.126 )/ 2 )
=540.393/3677.453
=14.69 %

Beijing Tong Ren Tang Chinese Medicine Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=548.706/( (3530.109+3810.126)/ 2 )
=548.706/3670.1175
=14.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Beijing Tong Ren Tang Chinese Medicine Co  (HKSE:03613) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Beijing Tong Ren Tang Chinese Medicine Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) Business Description

Traded in Other Exchanges
Address
Convention Plaza, 1 Harbour Road, Room 1405-1409, Office Tower, Wanchai, Hong Kong, HKG
Beijing Tong Ren Tang Chinese Medicine Co Ltd is a pharmaceutical retailer that specializes in Chinese medicine operating in three segments; Hong Kong includes the sale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments through retail and wholesale of Chinese medicine products and healthcare products, Mainland China (PRC, but excluding Hong Kong, Macao, and Taiwan) includes wholesale of healthcare products in Mainland China and the sole distributor of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd, and Overseas includes retail and wholesale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments.

Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) Headlines

No Headlines